Massachusetts–based startup TransMolecular announced in recent weeks that it had completed a phase 1 trial of its radiolabeled synthetic analog of the scorpion venom peptide chlorotoxin (131 I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback